Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Transfusion ; 61(2): 641-648, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33616945

RESUMEN

BACKGROUND: Pathogen reduction technology and enhanced bacterial culture screening promise to significantly reduce the risk of transfusion-associated septic reactions due to contaminated platelets. Recent reports suggest that these interventions lack efficacy for post-collection and processing contamination with environmental organisms if the storage bag integrity is compromised. CASE REPORT: We report a fatal septic transfusion reaction in a 63-year-old patient with chronic kidney and liver disease who received a pathogen reduced platelet transfusion in anticipation of surgery. METHODS: The residual platelet concentrate was cultured, with the detected microorganisms undergoing 16S genotype sequencing. Separate pathogen reduction studies were performed on the recovered bacteria, including assessment for amotosalen photoproducts. The storage container was subjected to pressure testing and microscopic examination. Environmental culture screening was performed at the hospital. RESULTS: Gram negative rods were detected in the platelet unit and cultures of both platelet component and the patient's blood grew Acinetobacter baumannii complex, Leclercia adecarboxylata and Staphylococcus saprophyticus. These strains were effectively inactivated with >7.2, 7.7, and >7.1 log10 kill, respectively. The platelet storage container revealed a leak visible only on pressure testing. Hospital environmental cultures were negative and the contamination source is unknown. A. baumannii complex and S. saprophyticus 16S genotyping sequences were identical to those implicated in a previously reported septic reaction. CONCLUSION: Findings are compatible with post-processing environmental contamination of a pathogen reduced platelet concentrate via a non-visible, acquired storage container leak. Efforts are warranted to actively prevent damage to, and detect defects in, platelet storage containers, and to store and transport components in clean environments.


Asunto(s)
Infecciones por Acinetobacter/etiología , Coinfección/etiología , Infección Hospitalaria/etiología , Infecciones por Enterobacteriaceae/etiología , Contaminación de Equipos , Falla de Equipo , Transfusión de Plaquetas/efectos adversos , Transfusión de Plaquetas/instrumentación , Sepsis/etiología , Infecciones Estafilocócicas/etiología , Reacción a la Transfusión/etiología , Infecciones por Acinetobacter/microbiología , Acinetobacter baumannii/aislamiento & purificación , Plaquetas/microbiología , Patógenos Transmitidos por la Sangre/efectos de los fármacos , Patógenos Transmitidos por la Sangre/efectos de la radiación , Coinfección/microbiología , Infección Hospitalaria/microbiología , Enterobacteriaceae/aislamiento & purificación , Infecciones por Enterobacteriaceae/microbiología , Resultado Fatal , Furocumarinas , Fracturas de Cadera/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Sepsis/microbiología , Infecciones Estafilocócicas/microbiología , Staphylococcus saprophyticus/aislamiento & purificación , Trombocitopenia/complicaciones , Trombocitopenia/terapia , Reacción a la Transfusión/microbiología , Rayos Ultravioleta
2.
Cardiovasc Diagn Ther ; 8(3): 316-324, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30057878

RESUMEN

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder of blood vessel formation resulting in mucocutaneous telangiectasias and visceral arteriovenous malformations. Nearly half of patients with HHT will have pulmonary arteriovenous malformations (PAVM) that place them at risk for potentially fatal complications that can occur when blood bypasses the pulmonary capillary circulation or as a result of PAVM rupture. Other manifestations of HHT outside the lung may increase the rate and severity of PAVM complications, creating unique clinical challenges. Management hinges on timely screening and diagnosis, followed by treatment of amenable PAVMs with transcatheter embolization in conjunction with medical management and prophylactic measures to treat and prevent complications. The purpose of this review is to highlight the clinical manifestations of PAVMs specific to patients with HHT and to detail screening and treatment strategies that can reduce the risk of developing life-threatening complications.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA